Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Event, Webcast

Pfizer Invites Shareholders to Attend Virtual-Only 2021 Annual Meeting of Shareholders on April 22


Pfizer Inc. (NYSE: PFE) announced today that shareholders and the general public are invited to access its virtual-only 2021 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 22, 2021. As previously disclosed, this year's meeting will be held virtually due to continued public health concerns related to the COVID-19 pandemic and to support the health and well-being of our shareholders and other meeting participants. We have designed the virtual Annual Meeting to ensure that our shareholders who attend the virtual Annual Meeting will be afforded comparable rights and opportunities to participate as they would at an in-person meeting.

Beginning today, shareholders can find additional information on accessing and registering for the virtual meeting at www.meetingcenter.io/274898886. If prompted for a password, please enter PFE2021. On the day of the Annual Meeting, shareholders may begin logging into the virtual meeting platform at 8:45 a.m. EDT using either a 15- or 16-digit control number found on their proxy card, voting instruction form or the notice that was previously received. Only shareholders who log into the meeting using a control number will have the ability to ask questions or vote during the live meeting.

Shareholders also may submit questions in advance of the meeting by following the instructions provided on the "Rules of Conduct and Meeting Procedures" available on the virtual meeting platform. The deadline for submitting questions in advance of the meeting is 5:00 p.m. EDT on April 21. Both registered and most beneficial shareholders will be able to vote their shares during the meeting by following the instructions provided on the virtual meeting platform. Some beneficial owners may be required to obtain a legal proxy and pre-register for the virtual meeting in order to vote or ask questions during the live meeting. Beneficial owners should check with their broker as to whether pre-registration is required. In addition, beneficial owners will be required to obtain a legal proxy and pre-register in order to submit questions in advance of the live meeting.

Guests may participate in a listen-only mode. No control number is required. A replay of the webcast will be available for one year at: https://investors.pfizer.com/events-and-presentations/default.aspx.

About Pfizer: Breakthroughs That Change Patients' Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice: The webcast may include forward-looking statements about, among other things, our anticipated operating and financial performance, reorganizations, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; manufacturing and product supply; our efforts to respond to COVID-19, including the Pfizer-BioNTech COVID-19 vaccine and our investigational protease inhibitor; and our expectations regarding the impact of COVID-19 on our business, operations and financial results that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. A description of these risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.


These press releases may also interest you

at 07:50
The "Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions" report has been added to...

at 07:48
Arçelik, the world's leading manufacturer of household appliances, announced today it will rename its global operations under one international...

at 07:45
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030 The global market for Laboratory...

at 07:42
Reference is made to Akastor ASA's (OSE: AKAST) announcement dated 18 April 2024 on the arbitration award issued in respect of the DRU contracts. Payment of the principal sums awarded, in total USD 108 million (exclusive interest), has now been...

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
IonQ , a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ's upcoming Annual...



News published on and distributed by: